T32603
2-Thiophenecarboxylic acid
ReagentPlus®, 99%
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C5H4O2S
Número CAS:
Peso molecular:
128.15
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
208-423-4
Beilstein/REAXYS Number:
110150
MDL number:
Assay:
99%
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
product line
ReagentPlus®
assay
99%
bp
260 °C (lit.)
mp
125-127 °C (lit.)
SMILES string
OC(=O)c1cccs1
InChI
1S/C5H4O2S/c6-5(7)4-2-1-3-8-4/h1-3H,(H,6,7)
InChI key
QERYCTSHXKAMIS-UHFFFAOYSA-N
Legal Information
ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Mrinal K Bera et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 17(42), 11838-11843 (2011-09-08)
Herein, we describe our attempts to systematically prepare a series of oligo(2-thienyl)-substituted pyridine derivatives. The crucial starting material, a β-alkoxy-β-ketoenamide, is easily available on a large scale by the reaction of lithiated methoxyallene with thiophene-2-carbonitrile and thiophene-2-carboxylic acid. This three-component
Sophie Le Pogam et al.
Journal of virology, 80(12), 6146-6154 (2006-05-30)
Multiple nonnucleoside inhibitor binding sites have been identified within the hepatitis C virus (HCV) polymerase, including in the palm and thumb domains. After a single treatment with a thumb site inhibitor (thiophene-2-carboxylic acid NNI-1), resistant HCV replicon variants emerged that
Matthew F McCown et al.
Antimicrobial agents and chemotherapy, 53(5), 2129-2132 (2009-03-11)
In vitro, telaprevir selects subtype-specific resistance pathways for hepatitis C virus GT-1a and GT-1b, as described to have occurred in patients. In GT-1a, the HCV-796 resistance mutation C316Y has low replication capacity (7%) that can be compensated for by the